Table I.

Main characteristics of eligible studies.

First author, year	Country	Antibody supplier	Total cases, n	Events, n	Risk of cancer	Follow-up outcome	Quality score	(Refs.)
Andriani et al, 2018	Italy	NS	57	28	Raised	NS	8	(17)
Duan et al, 2017	China	Invitrogen; Thermo Fisher Scientific, Inc.	32	18	Raised	Negative	7	(19)
Koumiya et al, 2016	Japan	Abcam	200	145	Raised	NS	7	(20)
Koukourakis et al, 2003	Greece	Abcam	113	107	Raised	NS	9	(28)
Zhang et al, 2012	China	Fuzhou Maixin Biotech Co., Ltd.	89	63	Raised	NS	8	(25)
Zheng et al, 2014	China	Bostik	71	44	Raised	NS	8	(29)
Zheng et al, 2015	China	NS	71	40	Raised	NS	8	(30)
Huang et al, 2012	China	R&D Systems, Inc.	105	57	Raised	NS	8	(26)
Xu et al, 2019	China	Abcam	90	54	Raised	NS	8	(31)
Kurtul et al, 2014	Turkey	BIOSS	84	NS	Raised	Negative	8	(22)
Fabrizio et al, 2020	Italy	Cell Signaling Technology, Inc.	21	NS	Raised	NS	7	(15)
Yin et al, 2016	China	NS	NS	NS	Raised	NS	7	(24)
Gao et al, 2020	China	NS	NS	NS	Raised	NS	8	(16)
Li et al, 2018	USA	NS	NS	NS	NS	NS	7	(18)
Ma et al, 2006	China	NS	NS	NS	NS	NS	7	(27)
Zheng et al, 2016	China	NS	NS	NS	Raised	Negative	8	(21)
Grant et al, 2014	USA	Prolytix	19	7	Raised	NS	8	(23)

The quality score is based on the Newcastle-Ottawa Oncomine scale. NS, not specified.